{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:57:06Z","timestamp":1794614226694,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01293-x","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T17:29:08Z","timestamp":1746206948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group"],"prefix":"10.1038","volume":"15","author":[{"given":"Ruoxuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3115-2780","authenticated-orcid":false,"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1881-8313","authenticated-orcid":false,"given":"Jiayu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengkai","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-7945","authenticated-orcid":false,"given":"Xiaodong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-5894","authenticated-orcid":false,"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0152-639X","authenticated-orcid":false,"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"1293_CR1","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","volume":"100","author":"JC Byrd","year":"2002","unstructured":"Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325\u201336.","journal-title":"Blood"},{"key":"1293_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354\u201365.","journal-title":"Blood"},{"key":"1293_CR3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.hoc.2011.09.018","volume":"25","author":"D Grimwade","year":"2011","unstructured":"Grimwade D, Mrozek K. Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. Hematol Oncol Clin North Am. 2011;25:1135\u201361.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1293_CR4","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood.V90.11.4532","volume":"90","author":"K Mrozek","year":"1997","unstructured":"Mrozek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PR, Rao KW, et al. Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood. 1997;90:4532\u20138.","journal-title":"Blood"},{"key":"1293_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1309\/RX27R8GJQM330C22","volume":"122","author":"MC Cox","year":"2004","unstructured":"Cox MC, Panetta P, Lo-Coco F, Del Poeta G, Venditti A, Maurillo L, et al. Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients. Am J Clin Pathol. 2004;122:298\u2013306.","journal-title":"Am J Clin Pathol"},{"key":"1293_CR6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/leu.2012.319","volume":"27","author":"Y Chen","year":"2013","unstructured":"Chen Y, Kantarjian H, Pierce S, Faderl S, O\u2019Brien S, Qiao W, et al. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013;27:836\u201342.","journal-title":"Leukemia"},{"key":"1293_CR7","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.2008.16.7981","volume":"27","author":"J Krauter","year":"2009","unstructured":"Krauter J, Wagner K, Schafer I, Marschalek R, Meyer C, Heil G, et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2009;27:3000\u20136.","journal-title":"J Clin Oncol"},{"key":"1293_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0268-960X(03)00040-7","volume":"18","author":"K Mrozek","year":"2004","unstructured":"Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115\u201336.","journal-title":"Blood Rev"},{"key":"1293_CR9","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1182\/blood-2003-02-0434","volume":"102","author":"C Schoch","year":"2003","unstructured":"Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003;102:2395\u2013402.","journal-title":"Blood"},{"key":"1293_CR10","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","volume":"28","author":"CJ Harrison","year":"2010","unstructured":"Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28:2674\u201381.","journal-title":"J Clin Oncol"},{"key":"1293_CR11","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gr\u00f6ger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988\u20131005.","journal-title":"Leukemia"},{"key":"1293_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1293_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/00043426-199511000-00001","volume":"17","author":"JA Martinez-Climent","year":"1995","unstructured":"Martinez-Climent JA, Espinosa R 3rd, Thirman MJ, Le Beau MM, Rowley JD. Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias. Identification of the t(9;11) as an indicator of long survival. J Pediatr Hematol Oncol. 1995;17:277\u201383.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1293_CR14","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","volume":"114","author":"BV Balgobind","year":"2009","unstructured":"Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489\u201396.","journal-title":"Blood"},{"key":"1293_CR15","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.22.02120","volume":"41","author":"RE van Weelderen","year":"2023","unstructured":"van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, et al. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2023;41:2963\u201374.","journal-title":"J Clin Oncol"},{"key":"1293_CR16","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1200\/JCO.20.03048","volume":"39","author":"JA Pollard","year":"2021","unstructured":"Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, et al. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children\u2019s Oncology Group Trial AAML0531. J Clin Oncol. 2021;39:3149\u201360.","journal-title":"J Clin Oncol"},{"key":"1293_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/leu.2010.316","volume":"17","author":"M Pigazzi","year":"2011","unstructured":"Pigazzi M, Masetti R, Bresolin S, Beghin A, Di Meglio A, Gelain S, et al. MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia. 2011;17:560\u20133.","journal-title":"Leukemia"},{"key":"1293_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ajh.23595","volume":"89","author":"Y Wang","year":"2014","unstructured":"Wang Y, Liu QF, Qin YZ, Liu DH, Xu LP, Jiang B, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of patients with mixed-lineage-leukemia-rearranged acute leukemia: Results from a prospective, multi-center study. Am J Hematol. 2014;89:130\u20136.","journal-title":"Am J Hematol"},{"key":"1293_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00976-1","volume":"14","author":"Y Cao","year":"2024","unstructured":"Cao Y, Huo W, Huang J, Yang Y, Wang Y, Chang Y, et al. MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study. Blood Cancer J. 2024;14:8.","journal-title":"Blood Cancer J"},{"key":"1293_CR20","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1182\/bloodadvances.2021004322","volume":"5","author":"J Lambert","year":"2021","unstructured":"Lambert J, Lambert J, Thomas X, Marceau-Renaut A, Micol JB, Renneville A, et al. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Adv. 2021;5:5258\u201368.","journal-title":"Blood Adv"},{"key":"1293_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00591-4","volume":"11","author":"S Yu","year":"2021","unstructured":"Yu S, Lin T, Nie D, Zhang Y, Sun Z, Zhang Q, et al. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes. Blood Cancer J. 2021;11:195.","journal-title":"Blood Cancer J"},{"key":"1293_CR22","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1182\/bloodadvances.2024013182","volume":"8","author":"A Venditti","year":"2024","unstructured":"Venditti A, Piciocchi A, Candoni A, Arena V, Palmieri R, Fil\u00ec C, et al. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial. Blood Adv. 2024;8:4410\u20133.","journal-title":"Blood Adv"},{"key":"1293_CR23","doi-asserted-by":"publisher","first-page":"963689723122582","DOI":"10.1177\/09636897231225821","volume":"33","author":"B Jiang","year":"2024","unstructured":"Jiang B, Zhao Y, Luo Y, Yu J, Chen Y, Ye B, et al. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring KMT2A Rearrangement and Its Prognostic Factors. Cell Transpl. 2024;33:9636897231225821.","journal-title":"Cell Transpl"},{"key":"1293_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00277-021-04488-x","volume":"100","author":"J Liu","year":"2021","unstructured":"Liu J, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2021;100:1267\u201381.","journal-title":"Ann Hematol"},{"key":"1293_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13545-y","volume":"12","author":"Q Li","year":"2022","unstructured":"Li Q, Xing S, Zhang H, Mao X, Xiao M, Wang Y. FISH improves risk stratification in acute leukemia by identifying KMT2A abnormal copy number and rearrangements. Sci Rep. 2022;12:9585.","journal-title":"Sci Rep"},{"key":"1293_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/ped.13451","volume":"60","author":"Y Iijima-Yamashita","year":"2018","unstructured":"Iijima-Yamashita Y, Matsuo H, Yamada M, Deguchi T, Kiyokawa N, Shimada A, et al. Multiplex fusion gene testing in pediatric acute myeloid leukemia. Pediatr Int. 2018;60:47\u201351.","journal-title":"Pediatr Int"},{"key":"1293_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.21873\/cgp.20242","volume":"18","author":"I Panagopoulos","year":"2021","unstructured":"Panagopoulos I, Andersen K, Eilert-Olsen M, Zeller B, Munthe-Kaas MC, Buechner J, et al. Therapy-induced Deletion in 11q23 Leading to Fusion of KMT2A With ARHGEF12 and Development of B Lineage Acute Lymphoplastic Leukemia in a Child Treated for Acute Myeloid Leukemia Caused by t(9;11)(p21;q23)\/KMT2A-MLLT3. Cancer Genomics Proteom. 2021;18:67\u201381.","journal-title":"Cancer Genomics Proteom"},{"key":"1293_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.molonc.2012.06.004","volume":"6","author":"N Cerveira","year":"2012","unstructured":"Cerveira N, Lisboa S, Correia C, Bizarro S, Santos J, Torres L, et al. Genetic and clinical characterization of 45 acute leukemia patients with MLL gene rearrangements from a single institution. Mol Oncol. 2012;6:553\u201364.","journal-title":"Mol Oncol"},{"key":"1293_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.exphem.2009.03.004","volume":"37","author":"M Doubek","year":"2009","unstructured":"Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, et al. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. Exp Hematol. 2009;37:659\u201372.","journal-title":"Exp Hematol"},{"key":"1293_CR30","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/sj.leu.2402189","volume":"15","author":"A Andersson","year":"2001","unstructured":"Andersson A, H\u00f6glund M, Johansson B, Lassen C, Billstr\u00f6m R, Garwicz S, et al. Paired multiplex reverse-transcriptase polymerase chain reaction (PMRT-PCR) analysis as a rapid and accurate diagnostic tool for the detection of MLL fusion genes in hematologic malignancies. Leukemia. 2001;15:1293\u2013300.","journal-title":"Leukemia"},{"key":"1293_CR31","first-page":"4817","volume":"13","author":"LM Hoffmeister","year":"2021","unstructured":"Hoffmeister LM, Orhan E, Walter C, Niktoreh N, Hanenberg H, von Neuhoff N. et al. Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid. Leukemia. Cancers. 2021;13:4817.","journal-title":"Leukemia. Cancers"},{"key":"1293_CR32","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J-i, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet. 2015;47:1304\u201315.","journal-title":"Nat Genet"},{"key":"1293_CR33","unstructured":"Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)]. Zhonghua Xue Ye Xue Za Zhi. 2023;44:705\u201312."},{"key":"1293_CR34","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","volume":"66","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu QF, Lin R, Yang T, Xu YJ, Mo XD, et al. Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull (Beijing). 2021;66:2498\u2013505.","journal-title":"Sci Bull (Beijing)"},{"key":"1293_CR35","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","volume":"125","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125:3956\u201362.","journal-title":"Blood"},{"key":"1293_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1251509","volume":"13","author":"J Huang","year":"2023","unstructured":"Huang J, Zhao Y, Jiang C, Han D, Pan Z, Zhang Z, et al. Diagnostic efficiency of metagenomic next-generation sequencing for suspected infection in allogeneic hematopoietic stem cell transplantation recipients. Front Cell Infect Microbiol. 2023;13:1251509.","journal-title":"Front Cell Infect Microbiol"},{"key":"1293_CR37","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/s41409-023-02106-0","volume":"58","author":"Y Cao","year":"2023","unstructured":"Cao Y, Zhang C, Zhao X, Huang J, Zhang Z, Jiang C, et al. Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in China. Bone Marrow Transpl. 2023;58:1413\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"1293_CR38","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL. et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"1293_CR39","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1182\/blood.2024026605","volume":"144","author":"S Loo","year":"2024","unstructured":"Loo S, Potter N, Ivey A, O'Nions J, Moon R, Jovanovic J, et al. Pretransplant MRD detection offusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia. Blood.2024;144:2554\u20137.","journal-title":"Blood."},{"key":"1293_CR40","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1293_CR41","doi-asserted-by":"publisher","first-page":"26340","DOI":"10.1073\/pnas.2014732117","volume":"117","author":"M Bill","year":"2020","unstructured":"Bill M, Mr\u00f3zek K, Kohlschmidt J, Eisfeld AK, Walker CJ, Nicolet D, et al. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A. Proc Natl Acad Sci USA. 2020;117:26340\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1293_CR42","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/leu.2013.90","volume":"27","author":"V Grossmann","year":"2013","unstructured":"Grossmann V, Schnittger S, Poetzinger F, Kohlmann A, Stiel A, Eder C, et al. High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia. Leukemia. 2013;27:1933\u20136.","journal-title":"Leukemia"},{"key":"1293_CR43","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/leu.2015.143","volume":"29","author":"A Pigneux","year":"2015","unstructured":"Pigneux A, Labopin M, Maertens J, Cordonnier C, Volin L, Soci\u00e9 G, et al. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23\/MLL rearrangement (MLL-r AML). Leukemia. 2015;29:2375\u201381.","journal-title":"Leukemia"},{"key":"1293_CR44","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41375-024-02333-4","volume":"38","author":"A Hern\u00e1ndez-S\u00e1nchez","year":"2024","unstructured":"Hern\u00e1ndez-S\u00e1nchez A, Gonz\u00e1lez T, Sobas M, Str\u00e4ng E, Castellani G, Ab\u00e1igar M, et al. Rearrangements involving 11q23.3\/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study. Leukemia. 2024;38:1929\u201337.","journal-title":"Leukemia"},{"key":"1293_CR45","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1182\/bloodadvances.2020002457","volume":"4","author":"H Matsuo","year":"2020","unstructured":"Matsuo H, Yoshida K, Nakatani K, Harata Y, Higashitani M, Ito Y, et al. Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. Blood Adv. 2020;4:4623\u201331.","journal-title":"Blood Adv"},{"key":"1293_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00557-6","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11:162.","journal-title":"Blood Cancer J"},{"key":"1293_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00471-x","volume":"11","author":"M Jentzsch","year":"2021","unstructured":"Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Schulz J, et al. Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation. Blood Cancer J. 2021;11:80.","journal-title":"Blood Cancer J"},{"key":"1293_CR48","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI129126","volume":"130","author":"S Klossowski","year":"2020","unstructured":"Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Investig. 2020;130:981\u201397.","journal-title":"J Clin Investig"},{"key":"1293_CR49","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920\u20134.","journal-title":"Nature"},{"key":"1293_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/bjh.14778","volume":"179","author":"X-D Mo","year":"2017","unstructured":"Mo X-D, Lv M, Huang X-J. Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention. Br J Haematol. 2017;179:184\u201397.","journal-title":"Br J Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01293-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01293-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01293-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T18:03:26Z","timestamp":1746209006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01293-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1293"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01293-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}